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Abstract
Background: The preventive effect of fluralaner spot-on solution against transmission of Babesia canis by Dermacentor
reticulatus ticks was evaluated.
Findings: Sixteen dogs, tested negative for B. canis by polymerase chain reaction (PCR) and immunofluorescence assay
test (IFAT), were allocated to two study groups. On day 0, dogs in one group (n = 8) were treated once topically with
fluralaner spot-on solution (BravectoTM Spot-on Solution) according to label recommendations and dogs in the control
group (n = 8) remained untreated. On days 2, 28, 56, 70 and 84, all dogs were infested with 50 (±4) D. reticulatus ticks
harbouring B. canis, with tick in situ thumb counts 48 ± 4 h after each infestation. On day 90, ticks were removed from
all dogs and counted. Prior to each infestation, the presence of B. canis in the respective tick batch was confirmed by
PCR, and 12–16 % of ticks were found to be infected with B. canis. Efficacy against ticks was 99.5 and 99.3 % on days 4
and 58 after treatment, respectively and 100 % on all other days. Replacement dogs were included for any B. canis
infected control dog (in total 19). All control dogs (n = 27) became infected with B. canis, as confirmed by PCR,
performed every 7 days, and by IFAT, performed every 14 days after treatment. None of the eight treated dogs
became infected with B. canis, as they were tested negative by PCR and IFAT throughout the study until day
112. By comparing infected dogs in the treated group with infected dogs in the untreated control group, a
100 % preventive effect against B. canis transmission was demonstrated.
Conclusions: A single topical administration of fluralaner spot-on solution effectively prevented the
transmission of B. canis by infected D. reticulatus ticks over a 12-week period.
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Findings
Hypothesis
Fluralaner rapidly kills ticks within 12 h after tick at-
tachment [1], and the prevention of Babesia canis
transmission by oral treatment with fluralaner chew-
able tablets was already shown [2]. Recently, a new
formulation of fluralaner as BravectoTM Spot-on Solu-
tion became available [3]. Thus, the potential of
topically administered fluralaner to prevent B. canis
transmission was tested.
Methods and study set-up
The same methodology as already described by Taenzler
et al. [2] was applied to investigate the prevention of
B. canis transmission by topical fluralaner treatment
and, therefore, methods and study set-up are only
briefly summarized below. Ethical approval was obtained
by the ClinVet Animal Ethics Committee (CAEC) before
study start.
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Animal details
Sixteen healthy mixed breed dogs (eight males, eight
females; 1–8 years, 13.8–26.9 kg) tested negative for
B. canis by polymerase chain reaction (PCR) and im-
munofluorescence assay test (IFAT), were randomly
allocated to two study groups of eight dogs each.
Dogs were individually housed indoors, and fed a
standard commercially available dry dog food once
daily; drinking water was provided ad libitum.
Treatment
On day 0 (i.e. day of treatment), dogs in the treatment
group were treated once topically with fluralaner spot-
on solution according to the manufacturer’s label in-
structions. There was no evidence of mis-dosing such as
spillage or run-off/drip-off in any treated animal. Dogs
in the control group remained untreated.
Tick infestations and assessments
On days 2, 28, 56, 70 and 84, all dogs were infested with
50 (± 4) adult, unfed D. reticulatus ticks (European ori-
gin, sex ratio 1:1). Prior to each infestation, the presence
of B. canis was confirmed by PCR using 50 ticks of the
respective batch. Tick in situ thumb counts were per-
formed 48 ± 4 h after each infestation. On day 90, all
remaining ticks on each dog were removed and counted.
Animal health
After treatment, the health status of each animal was
monitored by physical examinations on a 7-day interval
and the rectal body temperature of each dog was mea-
sured thrice weekly. General health observations, noting
the dog as normal or abnormal, were performed once
daily starting 7 days prior to treatment until day 112
after treatment. If a dog was noted as abnormal or the
rectal body temperature was above or equal to 39.4 °C,
an additional physical examination was performed.
Blood analysis
If, one or more parameters during physical examination
were abnormal, a blood smear was made. Blood samples
for serum analysis for antibodies to B. canis (IFAT) and
for B. canis DNA detection (PCR) were collected on a
14-day interval and on a 7-day interval after treatment,
respectively [2].
Rescue treatment and replacement
Dogs confirmed positive for B. canis by blood smear
were rescue treated using imidocarb and diminazene [2]
and remained part of all health observations, but were
not subjected to subsequent tick infestations. PCR and
IFAT were performed on blood samples and after con-
firmation of a babesial infection by both analyses; these
dogs were finally excluded from the study. B. canis
positive control dogs were replaced by a B. canis nega-
tive replacement dog to ensure a sufficient number of
control dogs for tick infestations/counting. In total, 19
replacement dogs (ten males, nine females) were used;
thus, in the control group a total of 27 dogs were
included.
Efficacy evaluation
The statistical analysis was performed using the software
package SAS® (SAS Institute Inc., Cary, NC, USA, re-
lease 9.3). The experimental unit was the individual dog.
The percentage of efficacy against ticks was calculated
for the treatment group at each assessment time point
using geometric means with Abbott’s formula:
Efficacy (%) = 100 × (MC - MT)/MC, where MC is the
mean number of total live attached ticks on untreated
control dogs and MT the mean number of total live at-
tached ticks on treated dogs. Log-transformed counts
(xi = ln(xi + 1)) of live attached ticks were used to con-
firm the efficacy calculation. Significant differences were
Table 1 Mean tick counts and efficacy against ticks after single
topical treatment with fluralaner spot-on solution
Day 4 Mean tick counts a (control/treated) (n) 18.6/0.1
Efficacy (%) 99.5 b
Day 30 Mean tick counts a (control/treated) (n) 18.8/0.0
Efficacy (%) 100 b
Day 58 Mean tick counts a (control/treated) (n) 12.7/0.1
Efficacy (%) 99.3 b
Day 72 Mean tick counts a (control/treated) (n) 22.2/0.0
Efficacy (%) 100 b
Day 86 c Mean tick counts a (control/treated) (n) 23.0/0.0
Efficacy (%) 100 b
Day 90 c Mean tick counts a (control/treated) (n) 22.3/0.0
Efficacy (%) 100 b
aGeometric mean live attached ticks
bLog-transformed counts of ticks from the treated group were significantly
different (P < 0.0001) from log-transformed counts of the untreated control
group
cControl group: six dogs available for infestation, two dogs were tested
positive for B. canis on day 85 and excluded, efficacy calculation based on
four dogs
Table 2 Number of dogs with increased rectal body temperature
(RBT) and number of dogs tested positive for B. canis via blood
smear, PCR and IFAT
Study group RBT Blood smear PCR IFAT
≥ 39.4 °C [POS] [POS] [POS]
Untreated control (n) 19/27 27/27 27/27 27/27
Treatment group a (n) 1b/8 0/8 0/8 0/8
aTopical treatment with fluralaner spot-on solution
bRBT above or equal 39.4 °C was measured but not confirmed to be related to
an infection with B. canis as PCR and IFAT were negative throughout
the study
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assessed between the log-transformed counts of live at-
tached ticks in the treated group at each assessment
time point compared to the log-transformed counts of
the untreated control group using a linear mixed model
including study group as a fixed effect and block as a
random effect. The two-sided level of significance was
declared when p ≤ 0.05.
The percentage preventive effect against B. canis
transmission for the treatment group was calculated as
follows: Preventive effect (%) = 100 × (TC - TT)/TC,
where TC is the total number of infected dogs in the un-
treated group and TT is the total number of infected
dogs in the treated group. A dog was regarded infected
with B. canis, if it was tested positive by both IFAT and
PCR. Study groups were compared using the Fisher’s
exact test.
Results
No treatment-related adverse events were observed in
any of the eight dogs treated once topically with flurala-
ner. An efficacy against ticks at each assessment time
point between 99.3 and 100 % was achieved (Table 1).
At each infestation time point, 12–16 % of ticks were
found to be infected with B. canis by PCR analysis. The
infection model was regarded as valid as all 27 untreated
control dogs were infected with B. canis, as confirmed
positive for B. canis by blood smear, for babesial DNA
by PCR analysis, and for antibodies to B. canis by IFAT
after first or subsequent tick infestation (Table 2). Fur-
thermore, dogs in the control group developed clinical
signs referring to babesiosis as pale mucous membranes,
rectal body temperature above or equal to 39.4 °C,
depressed/listless general behaviour, enlarged lymph
nodes and enlarged spleen. In total, 19 replacement dogs
(ten male, nine female) were included in the control
group throughout the study, ensuring that at each tick
infestation time point, the control group consisted of
eight animals, which was possible for all infestation time
points except the last one on day 84. For tick challenge
on day 84 only six control animals were available, from
which two were tested positive by blood smear and PCR
analysis on day 85 and rescue treated, so that for tick in
situ thumb counting on day 86 the control group con-
sisted of only four animals. Efficacy calculation for day
86 and day 90 were therefore calculated with four con-
trol dogs.
None of the dogs treated with fluralaner spot-on solu-
tion developed any clinical signs referring to babesiosis.
An increased rectal body temperature was measured in
1 of 8 treated dogs, but was not confirmed to be related
to an infection with B. canis, as both, PCR and IFAT,
were negative throughout the study. None of the treated
dogs became infected with B. canis during the complete
study duration, as confirmed by the absence of anti-
bodies to B. canis in the IFAT and a negative test result
for babesial DNA by PCR analysis on any of the sched-
uled blood analysis time points up to 4 weeks after the
last tick infestation (Table 2). A 100 % preventive effect
against the transmission of B. canis by infected D. reticu-
latus ticks was achieved after single topical fluralaner
treatment (Table 3).
Competing interests
JL is employed at ClinVet and all other authors of this paper are employees
of MSD Animal Health. The study was conducted as part of a research
program to evaluate the potential of fluralaner to inhibit the transmission of
pathogens to hosts after tick attachment after topical fluralaner treatment.
Authors’ contributions
The study design, protocol and report of the study were prepared by JT, JL,
AH and RR. JL and his team at ClinVet were responsible for the animal
phase, data collection, and statistical calculations. All authors revised and
approved the final version.
Acknowledgements
The authors would like to thank all the staff at ClinVet for their assistance
and contribution to this study.
Author details
1MSD Animal Health Innovation GmbH, ZurPropstei, 55270 Schwabenheim,
Germany. 2ClinVet International, Uitsigweg, Bainsvlei, 9338 Bloemfontein, Free
State, South Africa.
Received: 23 November 2015 Accepted: 30 March 2016
References
1. Wengenmayer C, Williams H, Zschiesche E, Moritz A, Langenstein J, Roepke RK,
Heckeroth AR. The speed of kill of fluralaner (BravectoTM) against Ixodes ricinus
ticks on dogs. Parasit Vectors. 2014;7:525.
2. Taenzler J, Liebenberg J, Roepke RK, Heckeroth AR. Prevention of
transmission of Babesia canis by Dermacentor reticulatus ticks to dogs
treated orally with fluralaner chewable tablets (BravectoTM). Parasit Vectors.
2015;8:305.
3. European Commission. Community register of veterinary medicinal
products, Product information Bravecto. http://www.ema.europa.eu/ema/
index.jsp?curl=pages/medicines/veterinary/medicines/002526/vet_med_
000285.jsp&mid=WC0b01ac058001fa1c
Table 3 Preventive effect against the transmission of B. canis by
D. reticulatus ticks
Untreated control Treatment group a
Infected (n) 27/27 0/8
Non-infected (n) 0/27 8/8
Infected (%) 100 0
Prevention (%) - 100
P-value - 0.0002
atopical treatment with fluralaner spot-on solution
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